^
Association details:
| Biomarker: | NR4A3 rearrangement + KIT mutation |
|---|---|
| Cancer: | Sarcoma |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sustained response to imatinib in patient with extraskeletal myxoid chondrosarcoma and novel KIT mutation
Published date:
08/26/2021
Excerpt:
Tumour was also notable for NR4A3 gene region rearrangement and mutation in KIT exon 11 at position c.1669 T>G. Based on these findings, she was diagnosed with extraskeletal myxoid chondrosarcoma (EMC). The patient has been on imatinib, a tyrosine kinase inhibitor with activity against KIT, for 3 years with stable disease.
DOI:
10.1136/bcr-2021-242039
